Intarcia submits ITCA 650 application to FDA

Intarcia's submission of the NDA coincided with World Diabetes Day.
Intarcia's submission of the NDA coincided with World Diabetes Day. | File image
Intarcia Therapeutics has submitted its New Drug Application (NDA) for ITCA 650 to the U.S. Food and Drug Administration.
ITCA 650 was developed to treat Type 2 diabetes.
"It's very exciting for us to submit our NDA in close proximity to World Diabetes Day – a day created to drive for new and innovative solutions that respond to the rapidly growing unmet needs and threats facing hundreds of millions of patients and their doctors and payers around the world," Intarcia President and CEO Kurt Graves said. "During the past decade over 40 new pills and injections were approved for diabetes, however, the scary reality is that the majority of patients with Type 2 diabetes still have poor glycemic control and poor adherence to their pills and injections over time. These trends and the alarming amount of diabetes complications, costs, and lives lost on a daily basis have to be addressed with a real sense of urgency.”
Intarcia’s NDA submission for ITCA 650 coincided with World Diabetes Day, during National Diabetes Month. Both events shed light on Type 2 diabetes, one of the world’s fastest-growing health crises.
Want to get notified whenever we write about Intarcia Therapeutics, Inc. ?
Next time we write about Intarcia Therapeutics, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Intarcia Therapeutics, Inc. 1 Marina Park Drive Boston, MA - 02210